Advances in the understanding of the gabaergic neurobiology of FMR1 expanded alleles leading to targeted treatments for fragile X spectrum disorder

Current Pharmaceutical Design

Volumn 21, Issue 34, 2015, Pages 4972-4979

  Lozano, Reymundo ^a   Martinez Cerdeno, Veronica ^b,c   Hagerman, Randi J ^b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c SHRINERS HOSPITALS FOR CHILDREN NORTHERN CALIFORNIA   (United States)

Author keywords

ASD treatments; Autism; Clinical trials; Fragile X Spectrum Disorder; Fragile X Syndrome; Fragile X associated Tremor Ataxia Syndrome; FXS; FXSD; FXTAS; GABA; GABA system; GABAA; Targeted treatments

Indexed keywords

3ALPHA HYDROXY 5ALPHA PREGNAN 20 ONE; 4 AMINOBUTYRIC ACID; 4 AMINOBUTYRIC ACID A RECEPTOR; 4 AMINOBUTYRIC ACID RECEPTOR STIMULATING AGENT; ACAMPROSATE; ARBACLOFEN; FRAGILE X MENTAL RETARDATION PROTEIN; GABOXADOL; GANAXOLONE; RILUZOLE; FMR1 PROTEIN, HUMAN;

ALLELE; ARTICLE; AUTISM; BRAIN CORTEX; CLINICAL FEATURE; CLINICAL TRIAL (TOPIC); DRUG EFFECT; DRUG EFFICACY; DRUG TARGETING; FRAGILE X ASSOCIATED TREMOR ATAXIA SYNDROME; FRAGILE X SPECTRUM DISORDER; FRAGILE X SYNDROME; GABAERGIC SYSTEM; GENETIC DISORDER; HUMAN; NEUROBIOLOGY; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; ANIMAL; DRUG DESIGN; GENETICS; METABOLISM; MOLECULARLY TARGETED THERAPY; PROCEDURES;

ALLELES; ANIMALS; CLINICAL TRIALS AS TOPIC; DRUG DESIGN; FRAGILE X MENTAL RETARDATION PROTEIN; FRAGILE X SYNDROME; GABA AGONISTS; GAMMA-AMINOBUTYRIC ACID; HUMANS; MOLECULAR TARGETED THERAPY;

EID: 84947999161     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612821666150914121038     Document Type: Article

References (135)

1. Farzin F, Perry H, Hessl D, et al. Autism spectrum disorders and attention-deficit/hyperactivity disorder in boys with the fragile X premutation. J Develop Behav Pediatr 2006; 27(2 Suppl): S137-44.
2. Chonchaiya W, Au J, Schneider A, et al. Increased prevalence of seizures in boys who were probands with the FMR1 premutation and co-morbid autism spectrum disorder. Hum Genet 2012; 131(4): 581-9.
3. Lozano R, Rosero CA, Hagerman RJ. Fragile X spectrum disorders. Intractable Rare Dis Res 2014; 3(4): 134-46.
4. Liu Y, Winarni TI, Zhang L, Tassone F, Hagerman RJ. Fragile Xassociated tremor/ataxia syndrome (FXTAS) in grey zone carriers. Clin Genet 2013; 84(1): 74-7.
5. Hall D, Tassone F, Klepitskaya O, Leehey M. Fragile X-associated tremor ataxia syndrome in FMR1 gray zone allele carriers. Mov Disord 2012; 27(2): 296-300.
6. Loesch DZ, Sherwell S, Kinsella G, et al. Fragile X-associated tremor/ataxia phenotype in a male carrier of unmethylated full mutation in the FMR1 gene. Clin Genet 2012; 82(1): 88-92.
7. Santa Maria L, Pugin A, Alliende MA, et al. FXTAS in an unmethylated mosaic male with fragile X syndrome from Chile. Clin Genet 2014; 86(4): 378-82.
8. Pretto DI, Hunsaker MR, Cunningham CL, Greco CM, Hagerman RJ, Noctor SC, et al. Intranuclear inclusions in a fragile X mosaic male. Transl Neurodegener 2013; 2(1): 10.
9. Lubs HA. A marker X chromosome. Am J Hum Genet 1969; 21(3): 231-44.
10. Hatton DD, Sideris J, Skinner M, et al. Autistic behavior in children with fragile X syndrome: Prevalence, stability, and the impact of FMRP. Am J Med Genet A 2006; 140(17): 1804-13.
11. Harris SW, Hessl D, Goodlin-Jones B, et al. Autism profiles of males with fragile X syndrome. Am J Ment Retard 2008; 113(6): 427-38.
12. Davids JR, Hagerman RJ, Eilert RE. Orthopaedic aspects of fragile- X syndrome. J Bone Joint Surg Am 1990; 72(6): 889-96.
13. Pyeritz RE, Stamberg J, Thomas GH, Bell BB, Zahka KG, Bernhardt BA. The marker Xq28 syndrome ("Fragile-X Syndrome") in a retarded man with mitral valve prolapse. Johns Hopkins Med J 1982; 151(5): 231-7.
14. Hagerman RJ. The physical and behavioral phenotype. In: Hagerman RJ, Hagerman PJ, Eds. Fragile X syndrome: Diagnosis, treatment, and research. 3rd ed. Baltimore: The Johns Hopkins University Press 2002; pp. 3-109.
15. Berry-Kravis E, Grossman AW, Crnic LS, Greenough WT. Understanding fragile X syndrome. Curr Paediatr 2002; 12(4): 316-24.
16. Loesch DZ, Huggins RM, Hagerman RJ. Phenotypic variation and FMRP levels in fragile X. Ment Retard Dev Disabil Res Rev 2004; 10(1): 31-41.
17. Strom CM, Crossley B, Redman JB, et al. Molecular testing for Fragile X Syndrome: lessons learned from 119,232 tests performed in a clinical laboratory. Genet Med 2007; 9(1): 46-51.
18. Tassone F, Hagerman RJ, Chamberlain WD, Hagerman PJ. Transcription of the FMR1 gene in individuals with fragile X syndrome. Am J Med Genet 2000; 97(3): 195-203.
19. Tassone F, Longshore J, Zunich J, Steinbach P, Salat U, Taylor AK. Tissue-specific methylation differences in a fragile X premutation carrier. Clin Genet 1999; 55(5): 346-51.
20. Godler DE, Tassone F, Loesch DZ, et al. Methylation of novel markers of fragile X alleles is inversely correlated with FMRP expression and FMR1 activation ratio. Hum Mol Genet 2010; 19(8): 1618-32.
21. Tassone F, Hagerman RJ, Ikle DN, et al. FMRP expression as a potential prognostic indicator in fragile X syndrome. Am J Med Genet 1999; 84(3): 250-61.
22. Darnell JC, Klann E. The translation of translational control by FMRP: therapeutic targets for FXS. Nat Neurosci 2013; 16(11): 1530-6.
23. Fernandez E, Rajan N, Bagni C. The FMRP regulon: from targets to disease convergence. Front Neurosci 2013; 7: 191.
24. Bagni C, Greenough WT. From mRNP trafficking to spine dysmorphogenesis: the roots of fragile X syndrome. Nat Rev 2005; 6(5): 376-87.
25. Banerjee P, Schoenfeld BP, Bell AJ, et al. Short- and long-term memory are modulated by multiple isoforms of the fragile X mental retardation protein. J Neurosci 2010; 30(19): 6782-92.
26. Niere F, Wilkerson JR, Huber KM. Evidence for a fragile X mental retardation protein-mediated translational switch in metabotropic glutamate receptor-triggered Arc translation and long-term depression. J Neurosci 2012; 32(17): 5924-36.
27. Sharma A, Hoeffer CA, Takayasu Y, et al. Dysregulation of mTOR signaling in fragile X syndrome. J Neurosci 2010; 30(2): 694-702.
28. Bear MF, Huber KM, Warren ST. The mGluR theory of fragile X mental retardation. Trends Neurosci 2004; 27(7): 370-77.
29. Wang L, Berry-Kravis E, Wang P, Rathmell B, Carpenter R, Bear M. Arbaclofen treatment is associated with global behavioral improvement in fragile X syndrome (FXS): results of a randomized, controlled phase II trial. J Dev Behav Pediatr. in press.
30. Lozano R, Hare EB, Hagerman RJ. Modulation of the GABAergic pathway for the treatment of fragile X syndrome. Neuropsychiatr Dis Treat 2014; 10: 1769-79.
31. Greiss-Hess L, Hagerman RJ. Sertraline Treatment for Young Children with FXS - Preliminary Findings. 14th International Fragile X Conference; Anaheim, CA.
32. Hare EB, Hagerman RJ, Lozano R. Targeted treatments in fragile X syndrome. Expert Opin Orphan Drugs 2014; 2(6): 531-43.
33. Leigh MJ, Nguyen DV, Mu Y, et al. A randomized double-blind, placebo-controlled trial of minocycline in children and adolescents with fragile x syndrome. J Develop Behav Pediatr 2013; 34(3): 147-55.
34. Scharf SH, Jaeschke G, Wettstein JG, Lindemann L. Metabotropic glutamate receptor 5 as drug target for Fragile X syndrome. Curr Opin Pharmacol 2015; 20: 124-34.
35. Jacquemont S, Berry-Kravis E, Hagerman R, et al. The challenges of clinical trials in fragile X syndrome. Psychopharmacology (Berl) 2014; 231(6): 1237-50.
36. D'Hulst C, Kooy RF. The GABAA receptor: a novel target for treatment of fragile X? Trends Neurosci 2007; 30(8): 425-31.
37. Olmos-Serrano JL, Paluszkiewicz SM, Martin BS, Kaufmann WE, Corbin JG, Huntsman MM. Defective GABAergic neurotransmission and pharmacological rescue of neuronal hyperexcitability in the amygdala in a mouse model of fragile X syndrome. J Neurosci 2010; 30(29): 9929-38.
38. Paluszkiewicz SM, Martin BS, Huntsman MM. Fragile X syndrome: the GABAergic system and circuit dysfunction. Dev Neurosci 2011; 33(5): 349-64.
39. Gersak K, Meden-Vrtovec H, Peterlin B. Fragile X premutation in women with sporadic premature ovarian failure in Slovenia. Hum Reprod 2003; 18(8): 1637-40.
40. Cronister A, Schreiner R, Wittenberger M, Amiri K, Harris K, Hagerman RJ. Heterozygous fragile X female: historical, physical, cognitive, and cytogenetic features. Am J Med Genet 1991; 38(2- 3): 269-74.
41. Hunter JE, Epstein MP, Tinker SW, Charen KH, Sherman SL. Fragile X-associated primary ovarian insufficiency: evidence for additional genetic contributions to severity. Genet Epidemiol 2008; 32(6): 553-9.
42. Wheeler AC, Bailey DB, Berry-Kravis E, et al. Associated features in females with an FMR1 premutation. J Neurodev Disord 2014; 6.
43. Hagerman RJ, Leehey M, Heinrichs W, et al. Intention tremor, parkinsonism, and generalized brain atrophy in male carriers of fragile X. Neurology 2001; 57(1): 127-30.
44. Jacquemont S, Farzin F, Hall D, et al. Aging in individuals with the FMR1 mutation. Am J Ment Retard 2004; 109(2): 154-64.
45. Jacquemont S, Hagerman RJ, Hagerman PJ, Leehey MA. Fragile-X syndrome and fragile X-associated tremor/ataxia syndrome: two faces of FMR1. Lancet Neurol 2007; 6(1): 45-55.
46. Berry-Kravis E, Abrams L, Coffey SM, et al. Fragile X-associated tremor/ataxia syndrome: clinical features, genetics, and testing guidelines. Mov Disord 2007; 22(14): 2018-30.
47. Jacquemont S, Hagerman RJ, Leehey M, et al. Fragile X premutation tremor/ataxia syndrome: molecular, clinical, and neuroimaging correlates. Am J Hum Genet 2003; 72(4): 869-78.
48. Tassone F, Berry-Kravis EM, editors. The Fragile X-Associated Tremor Ataxia Syndrome (FXTAS). New York, NY: Springer Science+ Business Media 2010.
49. Hagerman RJ, Coffey SM, Maselli R, et al. Neuropathy as a presenting feature in fragile X-associated tremor/ataxia syndrome. Am J Med Genet A 2007; 143(19): 2256-60.
50. Bourgeois JA, Coffey SM, Rivera SM, et al. A review of fragile X premutation disorders: expanding the psychiatric perspective. J Clin Psychiatry 2009; 70(6): 852-62.
51. Bourgeois JA, Seritan AL, Casillas EM, et al. Lifetime prevalence of mood and anxiety disorders in fragile X premutation carriers. J Clin Psychiatry 2011; 72(2): 175-82.
52. Coffey SM, Cook K, Tartaglia N, et al. Expanded clinical phenotype of women with the FMR1 premutation. Am J Med Genet A 2008; 146A(8): 1009-16.
53. Soontarapornchai K, Maselli R, Fenton-Farrell G, et al. Abnormal nerve conduction features in fragile X premutation carriers. Arch Neurol 2008; 65(4): 495-8.
54. Grigsby J, Brega AG, Engle K, et al. Cognitive profile of fragile X premutation carriers with and without fragile X-associated tremor/ataxia syndrome. Neuropsychology 2008; 22(1): 48-60.
55. Hagerman R, Hagerman P. Advances in clinical and molecular understanding of the FMR1 premutation and fragile X-associated tremor/ataxia syndrome. Lancet Neurol 2013; 12(8): 786-98.
56. Loesch DZ, Cook M, Litewka L, et al. A low symptomatic form of neurodegeneration in younger carriers of the FMR1 premutation, manifesting typical radiological changes. J Med Genet 2008; 45(3): 179-81.
57. Cohen S, Masyn K, Adams J, et al. Molecular and imaging correlates of the fragile X-associated tremor/ataxia syndrome. Neurology 2006; 67(8): 1426-31.
58. Brunberg JA, Jacquemont S, Hagerman RJ, et al. Fragile X premutation carriers: characteristic MR imaging findings of adult male patients with progressive cerebellar and cognitive dysfunction. AJNR Am J Neuroradiol 2002; 23(10): 1757-66.
59. Hashimoto R, Javan AK, Tassone F, Hagerman RJ, Rivera SM. A voxel-based morphometry study of grey matter loss in fragile Xassociated tremor/ataxia syndrome. Brain 2011; 134(Pt 3): 863-78.
60. Wang JY, Hessl D, Schneider A, Tassone F, Hagerman RJ, Rivera SM. Fragile X-associated tremor/ataxia syndrome: influence of the FMR1 gene on motor fiber tracts in males with normal and premutation alleles. JAMA Neurol 2013; 70(8): 1022-9.
61. Wang JY, Hagerman RJ, Rivera SM. A multimodal imaging analysis of subcortical gray matter in fragile X premutation carriers. Mov Disord 2013; 28(9): 1278-84.
62. Hashimoto R, Srivastava S, Tassone F, Hagerman RJ, Rivera SM. Diffusion tensor imaging in male premutation carriers of the fragile X mental retardation gene. Mov Disord 2011; 26(7): 1329-36.
63. Adams JS, Adams PE, Nguyen D, et al. Volumetric brain changes in females with fragile X-associated tremor/ataxia syndrome (FXTAS). Neurology 2007; 69(9): 851-9.
64. Adams PE, Adams JS, Nguyen DV, et al. Psychological symptoms correlate with reduced hippocampal volume in fragile X premutation carriers. Am J Med Genet B Neuropsychiatr Genet 2010; 153B(3): 775-85.
65. Ariza J, Steward C, Rueckert F, et al. Dysregulated iron metabolism in the choroid plexus in fragile X-associated tremor/ataxia syndrome. Brain Res 2015; 1598: 88-96.
66. Hunsaker MR, Greco CM, Spath MA, et al. Widespread noncentral nervous system organ pathology in fragile X premutation carriers with fragile X-associated tremor/ataxia syndrome and CGG knock-in mice. Acta Neuropathol 2011; 122(4): 467-79.
67. Greco CM, Berman RF, Martin RM, et al. Neuropathology of fragile X-associated tremor/ataxia syndrome (FXTAS). Brain 2006; 129(Pt 1): 243-55.
68. Greco CM, Soontrapornchai K, Wirojanan J, Gould JE, Hagerman PJ, Hagerman RJ. Testicular and pituitary inclusion formation in fragile X associated tremor/ataxia syndrome. J Urol 2007; 177(4): 1434-7.
69. Muzar Z, Lozano R, Schneider A, et al. Methadone use in a male with the FMRI premutation and FXTAS. Am J Med Genet A 2015; 167(6): 1354-9.
70. Muzar Z, Adams PE, Schneider A, Hagerman RJ, Lozano R. Addictive substances may induce a rapid neurological deterioration in fragile X-associated tremor ataxia syndrome: A report of two cases. Intractable Rare Dis Res 2014; 3(4): 162-5.
71. Martinez-Cerdeno V, Lechpammer M, Lott A, Schneider A, Hagerman R. Fragile X-associated tremor/ataxia syndrome in a 36 year old man. JAMA Neurol. In press.
72. Hagerman PJ, Hagerman RJ. Fragile X-associated tremor/ataxia syndrome. Ann N Y Acad Sci 2015; 1338: 58-70.
73. Filley CM, Brown MS, Onderko K, et al. White matter disease and cognitive impairment in FMR1 premutation carriers. Neurology 2015.
74. Cao Z, Hulsizer S, Tassone F, et al. Clustered burst firing in FMR1 premutation hippocampal neurons: amelioration with allopregnanolone. Hum Mol Genet 2012; 21(13): 2923-35.
75. Soghomonian JJ, Martin DL. Two isoforms of glutamate decarboxylase: why? Trends Pharmacol Sci 1998; 19(12): 500-5.
76. Macdonald RL, Olsen RW. GABAA receptor channels. Ann Rev Neurosci 1994; 17: 569-602.
77. Blednov YA, Benavidez JM, Black M, et al. GABAA receptors containing rho1 subunits contribute to in vivo effects of ethanol in mice. PLoS One 2014; 9(1): e85525.
78. Couve A, Moss SJ, Pangalos MN. GABAB receptors: a new paradigm in G protein signaling. Mol Cell Neurosci 2000; 16(4): 296- 312.
79. Gruss M, Braun K. Alterations of amino acids and monoamine metabolism in male Fmr1 knockout mice: a putative animal model of the human fragile X mental retardation syndrome. Neural Plast 2001; 8(4): 285-98.
80. Davidovic L, Navratil V, Bonaccorso CM, Catania MV, Bardoni B, Dumas ME. A metabolomic and systems biology perspective on the brain of the fragile X syndrome mouse model. Genome Res 2011; 21(12): 2190-202.
81. Selby L, Zhang C, Sun QQ. Major defects in neocortical GABAergic inhibitory circuits in mice lacking the fragile X mental retardation protein. Neurosci Lett 2007; 412(3): 227-32.
82. D'Hulst C, Heulens I, Brouwer JR, et al. Expression of the GABAergic system in animal models for fragile X syndrome and fragile X associated tremor/ataxia syndrome (FXTAS). Brain Res 2009; 1253: 176-83.
83. Gantois I, Vandesompele J, Speleman F, et al. Expression profiling suggests underexpression of the GABA(A) receptor subunit delta in the fragile X knockout mouse model. Neurobiology of disease 2006; 21(2): 346-57.
84. D'Hulst C, De Geest N, Reeve SP, et al. Decreased expression of the GABAA receptor in fragile X syndrome. Brain Res 2006; 1121(1): 238-45.
85. Curia G, Papouin T, Seguela P, Avoli M. Downregulation of tonic GABAergic inhibition in a mouse model of fragile X syndrome. Cereb Cortex 2009; 19(7): 1515-20.
86. Hong A, Zhang A, Ke Y, El Idrissi A, Shen CH. Downregulation of GABA(A) beta subunits is transcriptionally controlled by Fmr1p. J Mol Neurosci 2012; 46(2): 272-5.
87. El Idrissi A, Ding XH, Scalia J, Trenkner E, Brown WT, Dobkin C. Decreased GABA(A) receptor expression in the seizure-prone fragile X mouse. Neurosci Lett 2005; 377(3): 141-6.
88. Adusei DC, Pacey LK, Chen D, Hampson DR. Early developmental alterations in GABAergic protein expression in fragile X knockout mice. Neuropharmacology 2010; 59(3): 167-71.
89. Kratovac S, Corbin JG. Developmental changes in expression of inhibitory neuronal proteins in the Fragile X Syndrome mouse basolateral amygdala. Brain Res 2013; 1537: 69-78.
90. Pacey LK, Tharmalingam S, Hampson DR. Subchronic administration and combination metabotropic glutamate and GABAB receptor drug therapy in fragile X syndrome. J Pharmacol Exp Ther 2011; 338(3): 897-905.
91. Wafford KA, Ebert B. Gaboxadol--a new awakening in sleep. Curr Opin Pharmacol 2006; 6(1): 30-6.
92. Olmos-Serrano JL, Corbin JG, Burns MP. The GABA(A) receptor agonist THIP ameliorates specific behavioral deficits in the mouse model of fragile X syndrome. Dev Neurosci 2011; 33(5): 395-403.
93. Heulens I, D'Hulst C, Van Dam D, De Deyn PP, Kooy RF. Pharmacological treatment of fragile X syndrome with GABAergic drugs in a knockout mouse model. Behav Brain Res 2012; 229(1): 244-9.
94. Qin M, Huang T, Kader M, et al. R-Baclofen Reverses a Social Behavior Deficit and Elevated Protein Synthesis in a Mouse Model of Fragile X Syndrome. Int J Neuropsychopharmacol 2015.
95. Henderson C, Wijetunge L, Kinoshita MN, et al. Reversal of disease- related pathologies in the fragile X mouse model by selective activation of GABAB receptors with arbaclofen. Sci Transl Med 2012; 4(152): 152ra28.
96. Kokate TG, Svensson BE, Rogawski MA. Anticonvulsant activity of neurosteroids: correlation with gamma-aminobutyric acidevoked chloride current potentiation. J Pharmacol Exp Ther 1994; 270(3): 1223-9.
97. Beekman M, Ungard JT, Gasior M, et al. Reversal of behavioral effects of pentylenetetrazol by the neuroactive steroid ganaxolone. J Pharmacol Exp Ther 1998; 284(3): 868-77.
98. Carter RB, Wood PL, Wieland S, et al. Characterization of the anticonvulsant properties of ganaxolone (CCD 1042; 3alphahydroxy- 3beta-methyl-5alpha-pregnan-20-one), a selective, highaffinity, steroid modulator of the gamma-aminobutyric acid(A) receptor. J Pharmacol Exp Ther 1997; 280(3): 1284-95.
99. Mann K, Kiefer F, Spanagel R, Littleton J. Acamprosate: recent findings and future research directions. Alcohol Clin Exp Res 2008; 32(7): 1105-10.
100. Pierrefiche O, Daoust M, Naassila M. Biphasic effect of acamprosate on NMDA but not on GABAA receptors in spontaneous rhythmic activity from the isolated neonatal rat respiratory network. Neuropharmacology 2004; 47(1): 35-45.
101. Erickson CA, Mullett JE, McDougle CJ. Brief report: acamprosate in fragile X syndrome. J Autism Dev Disord 2010; 40(11): 1412-6.
102. Erickson CA, Wink LK, Ray B, et al. Impact of acamprosate on behavior and brain-derived neurotrophic factor: an open-label study in youth with fragile X syndrome. Psychopharmacology (Berl) 2013; 228(1): 75-84.
103. Berry-Kravis EM, Hessl D, Rathmell B, et al. Effects of STX209 (arbaclofen) on neurobehavioral function in children and adults with fragile X syndrome: a randomized, controlled, phase 2 trial. Sci Transl Med 2012; 4(152): 152ra27.
104. Erickson CA, Veenstra-Vanderweele JM, Melmed RD, et al. STX209 (arbaclofen) for autism spectrum disorders: an 8-week open-label study. J Autism Dev Disord 2014; 44(4): 958-64.
105. Veenstra-Vanderweele JM, Sikich L, Melmed RD, et al. Randomized, controlled, phase 2 trial of STX209 for social function in ASD. International Meeting for Autism Research (IMFAR); May 1-4, 2013; San Sebastian, Spain.
106. Berry-Kravis E. Progress and hurdles in development of targeted treatments for fragile X syndrome. International Meeting for Autism Research (IMFAR); May 13-16, 2015; Salt Lake City, UT.
107. Brinton RD. Neurosteroids as regenerative agents in the brain: therapeutic implications. Nat Rev Endocrinol 2013; 9(4): 241-50.
108. Singh C, Liu L, Wang JM, et al. Allopregnanolone restores hippocampal- dependent learning and memory and neural progenitor survival in aging 3xTgAD and nonTg mice. Neurobiol Aging 2012; 33(8): 1493-506.
109. Djebaili M, Hoffman SW, Stein DG. Allopregnanolone and progesterone decrease cell death and cognitive deficits after a contusion of the rat pre-frontal cortex. Neuroscience 2004; 123(2): 349-59.
110. Djebaili M, Guo Q, Pettus EH, Hoffman SW, Stein DG. The neurosteroids progesterone and allopregnanolone reduce cell death, gliosis, and functional deficits after traumatic brain injury in rats. J Neurotrauma 2005; 22(1): 106-18.
111. Sayeed I, Parvez S, Wali B, Siemen D, Stein DG. Direct inhibition of the mitochondrial permeability transition pore: a possible mechanism for better neuroprotective effects of allopregnanolone over progesterone. Brain Res 2009; 1263: 165-73.
112. Palop JJ, Chin J, Roberson ED, et al. Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer's disease. Neuron 2007; 55(5): 697-711.
113. Tassone F, Greco CM, Hunsaker MR, et al. Neuropathological, clinical and molecular pathology in female fragile X premutation carriers with and without FXTAS. Genes Brain Behav 2012; 11(5): 577-85.
114. Wang JM, Johnston PB, Ball BG, Brinton RD. The neurosteroid allopregnanolone promotes proliferation of rodent and human neural progenitor cells and regulates cell-cycle gene and protein expression. J Neurosci 2005; 25(19): 4706-18.
115. Wang JM, Singh C, Liu L, et al. Allopregnanolone reverses neurogenic and cognitive deficits in mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 2010; 107(14): 6498-503.
116. Chen S, Wang JM, Irwin RW, Yao J, Liu L, Brinton RD. Allopregnanolone Promotes Regeneration and Reduces beta-Amyloid Burden in a Preclinical Model of Alzheimer's Disease. PLoS One 2011; 6(8): e24293.
117. Seritan AL, Nguyen DV, Mu Y, et al. Memantine for fragile XAssociated Tremor/Ataxia Syndrome: A Randomized, Double- Blind, Placebo-Controlled Trial. J Clin Psychiatry 2014; 75(3): 264-71.
118. Reddy DS. Neurosteroids: endogenous role in the human brain and therapeutic potentials. Prog Brain Res 2010; 186: 113-37.
119. Monaghan EP, McAuley JW, Data JL. Ganaxolone: a novel positive allosteric modulator of the GABA(A) receptor complex for the treatment of epilepsy. Expert Opin Investig Drugs 1999; 8(10): 1663-71.
120. Reddy DS, O'Malley BW, Rogawski MA. Anxiolytic activity of progesterone in progesterone receptor knockout mice. Neuropharmacology 2005; 48(1): 14-24.
121. Reddy DS. Pharmacology of endogenous neuroactive steroids. Crit Rev Neurobiol 2003; 15(3-4): 197-234.
122. Kerrigan JF, Shields WD, Nelson TY, et al. Ganaxolone for treating intractable infantile spasms: a multicenter, open-label, addon trial. Epilepsy Res 2000; 42(2-3): 133-9.
123. Laxer K, Blum D, Abou-Khalil BW, et al. Assessment of ganaxolone's anticonvulsant activity using a randomized, double-blind, presurgical trial design. Ganaxolone Presurgical Study Group. Epilepsia 2000; 41(9): 1187-94.
124. Monaghan EP, Navalta LA, Shum L, Ashbrook DW, Lee DA. Initial human experience with ganaxolone, a neuroactive steroid with antiepileptic activity. Epilepsia 1997; 38(9): 1026-31.
125. Bialer M, Johannessen SI, Levy RH, Perucca E, Tomson T, White HS. Progress report on new antiepileptic drugs: a summary of the Tenth Eilat Conference (EILAT X). Epilepsy Res 2010; 92(2-3): 89-124.
126. Bialer M, Johannessen SI, Kupferberg HJ, Levy RH, Perucca E, Tomson T. Progress report on new antiepileptic drugs: a summary of the Eighth Eilat Conference (EILAT VIII). Epilepsy Res 2007; 73(1): 1-52.
127. Kooy F, Heulens I, D'Hulst C, et al. The GABAA receptor as a potential target for therapy of the fragile X syndrome [abstract]. NFXF 12th International FX Conference; July 21 - 25; Detroit, MI.
128. Ristori G, Romano S, Visconti A, et al. Riluzole in cerebellar ataxia: a randomized, double-blind, placebo-controlled pilot trial. Neurology 2010; 74(10): 839-45.
129. Erickson CA, Weng N, Weiler IJ, et al. Open-label riluzole in fragile X syndrome. Brain Res 2011; 1380: 264-70.
130. Hagerman RJ, Berry-Kravis E, Kaufmann WE, et al. Advances in the treatment of fragile X syndrome. Pediatrics 2009; 123(1): 378- 90.
131. Leehey MA, Berry-Kravis E, Goetz CG, Hagerman R. Clinical Neurological Phenotype of FXTAS. In: Tassone F, Berry-Kravis E, Eds. The Fragile X-Associated Tremor Ataxia Syndrome (FXTAS) New York: Springer 2011; pp. 1-16.
132. Polussa J, Schneider A, Hagerman R. Molecular Advances Leading to Treatment Implications for Fragile X Premutation Carriers. Brain Disord Ther 2014; 3.
133. Berry-Kravis E. Mechanism-based treatments in neurodevelopmental disorders: fragile X syndrome. Pediatr Neurol 2014; 50(4): 297- 302.
134. Gross C, Hoffmann A, Bassell GJ, Berry-Kravis EM. Therapeutic Strategies in Fragile X Syndrome: From Bench to Bedside and Back. Neurotherapeutics 2015.
135. Fernandez-Ruiz J, Sagredo O, Pazos MR, et al. Cannabidiol for neurodegenerative disorders: important new clinical applications for this phytocannabinoid? Br J Clin Pharmacol 2013; 75(2): 323- 33.